CN Patent

CN1870997B — 角膜结膜病变的治疗剂

Assigned to Santen Pharmaceutical Co Ltd · Expires 2011-05-04 · 15y expired

What this patent protects

本发明目的是提供作为缩合杂环化合物的5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]噻唑烷-2，4-二酮或其盐的新型医药用途。5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]噻唑烷-2，4-二酮或其盐对干眼症模型发挥优良的治愈促近效果，作为干眼症、角膜溃疡、角膜炎、结膜炎、点状表层角膜症、角膜上皮缺损、结膜上皮缺损、干性角膜结膜炎、上轮部角膜结膜炎或线状角膜炎等角膜结膜病变的治疗剂是有效的。

USPTO Abstract

本发明目的是提供作为缩合杂环化合物的5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]噻唑烷-2，4-二酮或其盐的新型医药用途。5-[4-(6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基)苄基]噻唑烷-2，4-二酮或其盐对干眼症模型发挥优良的治愈促近效果，作为干眼症、角膜溃疡、角膜炎、结膜炎、点状表层角膜症、角膜上皮缺损、结膜上皮缺损、干性角膜结膜炎、上轮部角膜结膜炎或线状角膜炎等角膜结膜病变的治疗剂是有效的。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN1870997B
Jurisdiction: CN
Classification: —
Expires: 2011-05-04
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.